Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Senzime

4.885

 

SEK

 

-0.1 %

Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
764.58M SEK
Turnover
4.99M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
30.6.
2025

Extraordinary general meeting '25

18.7.
2025

Interim report Q2'25

7.11.
2025

Interim report Q3'25

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release6/12/2025, 11:30 AM

The first tranche of the directed share issue completed

Senzime
Press release6/3/2025, 6:51 AM

DNB Carnegie Access: Senzime: Strengthening its financials

Senzime
Regulatory press release6/2/2025, 5:30 PM

NOTICE OF extraordinary GENERAL MEETING in Senzime AB (PUBL)

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release6/2/2025, 5:15 PM

Senzime carries out directed share issue of SEK 110 million

Senzime
Press release5/26/2025, 12:30 PM

Senzime applauds announcement of upcoming European pediatric guidelines of neuromuscular monitoring

Senzime
Regulatory press release5/19/2025, 4:55 PM

BULLETIN from annual general meeting in Senzime AB (publ)

Senzime
Press release4/29/2025, 7:00 AM

Senzime secures new TetraGraph contract with state-wide university hospital system in southern US

Senzime
Regulatory press release4/24/2025, 1:30 PM

Senzime publishes Annual and Sustainability report for 2024

Senzime
Press release4/23/2025, 1:15 PM

Senzime secures new system-wide contract with major Pacific northwest US healthcare system

Senzime
Press release4/23/2025, 9:18 AM

Carnegie Access: Senzime: Confidence builder – Q1(25) review

Senzime
Press release4/22/2025, 12:45 PM

Carnegie Access: Senzime: Interview - Q1 2025 result presentation

Senzime
Press release4/22/2025, 8:21 AM

Carnegie Access: Senzime: Impressive growth – Q1(25) initial comments

Senzime
Regulatory press release4/22/2025, 6:30 AM

Interim report January-March 2025: 94 percent growth

Senzime
Press release4/16/2025, 1:11 PM

Carnegie Access: Senzime: Back on track – Q1 preview

Senzime
Press release4/14/2025, 1:00 PM

Invitation to presentation of Senzime’s first quarter 2025 report

Senzime
Regulatory press release4/14/2025, 9:50 AM

NOTICE OF ANNUAL GENERAL MEETING in Senzime AB (publ)

Senzime
Press release4/3/2025, 10:15 AM

Senzime comments on US market tariffs

Senzime
Regulatory press release4/1/2025, 6:40 AM

New number of shares and votes in Senzime AB (publ)

Senzime
Press release3/14/2025, 12:00 PM

Senzime secures additional US hospital system contracts

Senzime
Press release3/14/2025, 9:26 AM

Carnegie Access: Senzime: Highlights from Carnegie’s Healthcare Conference

Senzime
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.